Literature DB >> 24230466

Special aspects of interleukin-33 and the IL-33 receptor complex.

Michael U Martin1.   

Abstract

Interleukin-33 (IL-33) is an unconventional member of the IL-1 family: it is a dual function cytokine. Many different cell types, tissue cells and leukocytes, produce IL-33 either constitutively or after stimulation and release it by a poorly defined molecular mechanism. Free IL-33 acts as a classical cytokine by binding to target cells expressing receptors for IL-33 minimally consisting of ST2 and IL-1RAcP. Depending on the target cell type IL-33 will stimulate cell-type specific signal transduction mechanisms and thereby change the biosynthetic profile of the respective cell. In addition, it is stored in the nucleus of cells and may be released after cell stress, death by injury or necrosis, acting as an alarmin by orchestrating a sterile inflammation. Furthermore, IL-33 has intracrine functions in the cell producing it, which are independent of IL-33 receptors. Intracellular IL-33 is predominantly found in the nucleus associated to the chromatin and may exert gene regulatory function by yet poorly defined mechanisms. It is the aim of this review to address two basic biological aspects of the IL-33/IL-33 receptor system. First, to summarize the current understanding of the fate and function of intracellular IL-33, and second, to discuss recent advances in the knowledge of the molecular composition, function and regulation of the IL-33 receptor complex, including initial signaling mechanisms.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  IL-1RAcP; IL-33 receptor complex; IL-33 release; IL-33 signaling; Interleukin-33 processing; Intracellular IL-33; aa; amino acid; h; human; interleukin-1 receptor accessory protein; m; mouse

Mesh:

Substances:

Year:  2013        PMID: 24230466     DOI: 10.1016/j.smim.2013.10.006

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  26 in total

1.  A network map of IL-33 signaling pathway.

Authors:  Sneha M Pinto; Yashwanth Subbannayya; D A B Rex; Rajesh Raju; Oishi Chatterjee; Jayshree Advani; Aneesha Radhakrishnan; T S Keshava Prasad; Mohan R Wani; Akhilesh Pandey
Journal:  J Cell Commun Signal       Date:  2018-04-28       Impact factor: 5.782

2.  IL-17-producing ST2+ group 2 innate lymphoid cells play a pathogenic role in lung inflammation.

Authors:  Ting Cai; Jinxin Qiu; Yan Ji; Wenjing Li; Zhaoyun Ding; Caixia Suo; Jiali Chang; Jingjing Wang; Rui He; Youcun Qian; Xiaohuan Guo; Liang Zhou; Huiming Sheng; Lei Shen; Ju Qiu
Journal:  J Allergy Clin Immunol       Date:  2018-04-03       Impact factor: 10.793

Review 3.  Interleukin 33: a switch-hitting cytokine.

Authors:  Daniel O Villarreal; David B Weiner
Journal:  Curr Opin Immunol       Date:  2014-04-22       Impact factor: 7.486

4.  IL-33/ST2 axis promotes mast cell survival via BCLXL.

Authors:  Jun-Xia Wang; Shinjiro Kaieda; Sarah Ameri; Nadia Fishgal; Daniel Dwyer; Anthony Dellinger; Christopher L Kepley; Michael F Gurish; Peter A Nigrovic
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-30       Impact factor: 11.205

Review 5.  Interleukin 33 is a guardian of barriers and a local alarmin.

Authors:  Nikolas T Martin; Michael U Martin
Journal:  Nat Immunol       Date:  2016-02       Impact factor: 25.606

6.  Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer.

Authors:  Donye Dominguez; Cong Ye; Zhe Geng; Siqi Chen; Jie Fan; Lei Qin; Alan Long; Long Wang; Zhuoli Zhang; Yi Zhang; Deyu Fang; Timothy M Kuzel; Bin Zhang
Journal:  J Immunol       Date:  2016-12-23       Impact factor: 5.422

7.  The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells.

Authors:  Ajithkumar Vasanthakumar; Kazuyo Moro; Annie Xin; Yang Liao; Renee Gloury; Shimpei Kawamoto; Sidonia Fagarasan; Lisa A Mielke; Shoukat Afshar-Sterle; Seth L Masters; Susumu Nakae; Hirohisa Saito; John M Wentworth; Peng Li; Wei Liao; Warren J Leonard; Gordon K Smyth; Wei Shi; Stephen L Nutt; Shigeo Koyasu; Axel Kallies
Journal:  Nat Immunol       Date:  2015-01-19       Impact factor: 25.606

Review 8.  IL-33 and the intestine: The good, the bad, and the inflammatory.

Authors:  Zerina Hodzic; Ellen Merrick Schill; Alexa M Bolock; Misty Good
Journal:  Cytokine       Date:  2017-07-04       Impact factor: 3.861

Review 9.  IL-1 family members in the pathogenesis and treatment of metabolic disease: Focus on adipose tissue inflammation and insulin resistance.

Authors:  Dov B Ballak; Rinke Stienstra; Cees J Tack; Charles A Dinarello; Janna A van Diepen
Journal:  Cytokine       Date:  2015-07-17       Impact factor: 3.861

10.  Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33.

Authors:  Geethani Bandara; Michael A Beaven; Ana Olivera; Alasdair M Gilfillan; Dean D Metcalfe
Journal:  Eur J Immunol       Date:  2015-09-09       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.